Refractive errors are the most common ocular disorders globally, occurring when the eye's structural abnormalities prevent incoming light from focusing precisely on the retina, resulting in blurred vision. Core subtypes include Myopia (nearsightedness), Hyperopia (farsightedness), Astigmatism, and Presbyopia (age-related loss of near focusing ability, onset typically ≥40 years).
Mild to moderate refractive errors can be corrected with spectacles or contact lenses, while surgical correction is the definitive solution for long-term freedom from glasses. China has the largest volume of refractive surgeries in the world, with over 2 million procedures performed annually, and the surgical safety and efficacy are on par with top international centers.
China performs over 2 million refractive surgeries annually—the highest volume globally. Top centers have extensive experience across all modalities, with a surgical success rate exceeding 99% and postoperative satisfaction above 98%.
Femtosecond laser LASIK, SMILE/SMILE Pro, PRK/LASEK, PIOL, and RLE are all widely available. SMILE Pro is deployed in top centers with the latest equipment and optimized protocols.
LASIK costs USD 800–1,500 per eye, SMILE USD 1,200–2,000, and PIOL USD 2,000–3,500—only 1/3–1/5 of US prices. Surgery is arranged within 1–3 days, compared with 1–3 months in Europe and America.
Top centers provide complete preoperative examinations (corneal topography, pachymetry, axial length, tear film assessment) to develop personalized surgical plans. Multifocal/EDOF IOLs deliver excellent visual outcomes for presbyopia patients.
Standardized follow-up (1 day, 1 week, 1 month, 3 months, 6 months, 1 year) with timely management of complications. Postoperative visual quality and stability are on par with top European and American centers.
Cataract is the leading cause of reversible blindness worldwide, characterized by opacification of the natural crystalline lens. The global annual incidence is approximately 20 million new cases, with over 10 million cataract surgeries performed annually in China alone.
Core risk factors include aging (onset typically ≥60 years), diabetes, long-term corticosteroid use, ocular trauma, and UV exposure. Symptoms include progressively blurred vision, glare, faded color perception, and in severe cases complete vision loss. Surgery is the only definitive treatment; no medication can reverse cataract progression.
China performs over 10 million cataract surgeries annually. The surgical success rate (postoperative corrected VA ≥20/40) in top centers exceeds 98%. The serious complication rate (e.g., endophthalmitis) is <0.1%, lower than the global average.
FLACS is widely available in top centers with a 1–2 week waiting time (vs. 2–3 months in Europe/America). Premium IOLs (multifocal, EDOF, toric, light-adjustable) are available at 1/2–2/3 of US prices, with partial medical insurance coverage.
Phacoemulsification with monofocal IOL costs USD 800–1,500 per eye; FLACS with premium IOL costs USD 2,000–3,500—only 1/5–1/3 of US prices (USD 5,000–8,000). Surgery arranged within 1–3 days.
Top centers provide complete preoperative biometry, personalized IOL selection, refined surgical techniques, and standardized postoperative follow-up, ensuring excellent long-term visual outcomes and high patient satisfaction.
Glaucoma is a group of diseases characterized by progressive optic nerve damage and visual field loss, usually associated with elevated intraocular pressure (IOP). It is the second leading cause of irreversible blindness worldwide, affecting approximately 80 million people globally.
Core subtypes: Primary Open-Angle Glaucoma (POAG, 70% of cases, chronic/asymptomatic), Primary Angle-Closure Glaucoma (PACG, acute or chronic angle closure), Normal-Tension Glaucoma (NTG), Congenital Glaucoma, and Secondary Glaucoma (diabetes, uveitis, trauma). Surgery is indicated when maximum tolerated medical therapy fails to achieve target IOP.
China has the largest annual volume of glaucoma surgeries globally. The trabeculectomy success rate in top centers exceeds 85%, on par with top European and American centers.
MIGS (iStent, Hydrus, GATT) is widely available with a 1–2 week waiting time (vs. 2–3 months in Europe/America). MIGS combined with cataract surgery costs USD 2,000–3,000—only 1/3–1/2 of US prices.
Trabeculectomy costs USD 1,500–2,500; tube shunt implantation costs USD 3,000–5,000—only 1/5–1/3 of US prices. Surgery arranged within 1–2 weeks.
Top centers are equipped with OCT, visual field testing, and anterior segment imaging for early diagnosis. The MDT system integrates glaucoma specialists, cataract surgeons, and retinal specialists to provide comprehensive care.
Diabetic Retinopathy is a microvascular complication of diabetes, characterized by retinal ischemia, increased vascular permeability, and pathological neovascularization. It is the leading cause of vision loss in working-age adults globally, affecting over 100 million people.
Clinical staging: Non-Proliferative DR (NPDR, early stage with microaneurysms, hemorrhages, hard exudates, macular edema), and Proliferative DR (PDR, advanced stage with neovascularization, vitreous hemorrhage, tractional retinal detachment). Intravitreal anti-VEGF agents are first-line for diabetic macular edema and active PDR; surgery is reserved for advanced complications.
China performs over 500,000 PPV surgeries annually. The surgical success rate (retinal reattachment, vision improvement) in top centers exceeds 90%, on par with top international centers.
Intravitreal anti-VEGF agents are widely available with 1–2 week waiting time and low cost (USD 150–300 per injection, vs. USD 1,000–2,000 in the US). Multiple agents are covered by national medical insurance.
PPV surgery costs USD 2,000–3,500 in top Chinese centers—only 1/5–1/3 of US prices (USD 10,000–15,000). Surgery arranged within 1–2 weeks.
Top centers provide early DR screening, anti-VEGF therapy, laser photocoagulation, PPV surgery, and long-term follow-up, significantly reducing the risk of severe vision loss.
Corneal disorders affect the clear, dome-shaped anterior surface of the eye, which is responsible for ~70% of the eye's total focusing power. Corneal damage, dystrophy, or infection causes opacification, irregular astigmatism, and severe vision loss.
Common subtypes: Keratoconus, Fuchs' Endothelial Dystrophy, infectious keratitis, corneal scarring, bullous keratopathy, and anterior corneal dystrophies. Etiology includes genetic predisposition, ocular trauma, infection (bacterial/viral/fungal), long-term contact lens wear, and prior intraocular surgery. Clinical presentation: blurred vision, eye pain, photophobia, redness, tearing, and corneal opacification.
China performs over 15,000 corneal transplantations annually, with the largest EK (DSAEK/DMEK) volume in Asia. The 5-year graft survival rate in top centers exceeds 90%, on par with top international centers.
CXL is widely available in top Chinese centers, with a >95% success rate in halting keratoconus progression. The cost is only USD 800–1,500 per eye—1/3–1/2 of US and European prices.
PK costs USD 3,000–5,000; EK costs USD 4,000–6,000; DALK costs USD 3,500–5,500—only 1/3–1/2 of US prices. Surgery arranged within 1–2 weeks.
Top centers are equipped with corneal topography, anterior segment OCT, and endothelial cell counting for precise diagnosis and personalized treatment planning. The full-cycle management system ensures excellent long-term graft survival.
Strabismus is a disorder characterized by misalignment of the eyes, where the eyes do not properly align with each other when looking at an object. It affects approximately 2–4% of the population, and early intervention (in childhood) is associated with superior binocular vision outcomes.
Core subtypes: Esotropia (inward turn), Exotropia (outward turn), Hypertropia/Hypotropia (upward/downward turn), and Cyclotropia (torsional misalignment). Strabismus can cause diplopia, amblyopia ("lazy eye"), and psychosocial distress from cosmetic concerns. Surgical correction is the definitive treatment for strabismus that cannot be corrected with glasses, prisms, or vision therapy.
China has the largest number of strabismus surgeries performed annually in the world. Top centers have extensive experience in complex strabismus cases (including reoperations), with a surgical success rate exceeding 90% and a low complication rate.
Top centers use advanced diagnostic tools (ocular motility examination, prism cover test, OCT, and orbital imaging) to develop personalized surgical plans. Adjustable suture techniques are widely used, allowing postoperative refinement of alignment.
Strabismus surgery costs USD 1,500–3,000 per eye in top Chinese centers—only 1/3–1/2 of US prices (USD 5,000–8,000). Surgery can be arranged within 1–2 weeks, while the waiting period in Europe and America is often 1–3 months.
Top centers provide complete postoperative follow-up and vision therapy (orthoptics) to improve binocular vision and prevent amblyopia, especially for pediatric patients. The integrated treatment system ensures excellent long-term outcomes.